KR100517899B1 - Bioconversion ginseng composite using microorganism and fabrication method thereof - Google Patents

Abstract

In the ginseng composition, the ratio of (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside Rb1 + Ginsenoside Rb2) is 0.1 or more. To provide a bioconversion ginseng composition.

In addition, in the ginseng composition, the ratio of (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside Rb1 + Ginsenoside Rb2) is 0.1 or more. It provides a bioconverted ginseng composition, characterized in that used as an anti-allergic substance by inhibiting the release of histamine when absorbed into the human body.

In addition, the present invention provides a method for producing a ginseng composition, the biological conversion process of suspending the ginseng raw material in water and then adding lactic acid bacteria and cultured around 24 hours to 72 hours to obtain a bio-converted ginseng solution; Concentrating or freezing / drying the bio-converted ginseng solution through the above process, or centrifugation of the bio-converted ginseng solution and filtering the supernatant only to obtain a bio-converted ginseng concentrate, characterized in that the bioconversion ginseng composition comprising the It provides a manufacturing method.

Description

BIOCONVERSION GINSENG COMPOSITE USING MICROORGANISM AND FABRICATION METHOD THEREOF

The present invention relates to a ginseng composition and a method for producing the same, and more particularly, to a bio-converted ginseng composition and a method for producing the same, wherein the anticancer component is enhanced through a process for treating lactic acid bacteria or enterobacteriaceae. The present application reveals that it is a domestic priority claim application based on Korean Patent Application No. 2002-5369 (2002.01.30) "Method for producing a bioconverted ginseng composition."

Typically, ginseng is a perennial root of perennial root of the genus Oga in ginseng, and about 11 species are known on the earth.

1) Korean Ginseng: Panax ginseng C.A.Meyer

 -It is native to the Far East of Asia (North 33 ~ 48: Korea, Northern Manchuria, and parts of Russia).

2) American Ginseng: Panax quinquefolium L.

 -Grown and grown in the United States and Canada.

3) Panax Notoginseng: Panax notoginseng F.H.Chen

 -Wild or cultivated in southwestern Guangxi province from southeastern Yunnan Province of China.

4) Panax japonicus: Panax japonicus C.A.Meyer

 -It is distributed in Japan, southwest China, and Nepal.

The ginseng has been used for various diseases such as psychiatry, diseases of the nervous system and diabetes in the form of herbal medicine mainly in Asian countries such as Korea, China, Japan, and saponins, which are the main components of the ginseng, are tonic, tonic, soothing and hematopoietic. And antihypertensive effects have been demonstrated.

In particular, as the microbial metabolites IH-901, IH-902, IH-903 and IH-904 of the ginseng saponin have been demonstrated to have not only immune enhancing but also very potent tumor angiogenesis and cancer cell metastasis. The development of anticancer ginseng composition using the same is required. <Table 1> is a table supporting the effects of cancer cell metastasis such as IH-901, and after transplanting cancer cells to mice, 0.5 mg of the drug was orally administered for 5 days from the next day. The result of having measured the colony number of cancer is shown.

input         ingredient Pulmonary metastasis       colony number Cancer metastasis        Suppression rate Difference       (% control) IH-901 167.6 ± 62.0 39.1 ± 22.1 p <0.05 IH-902 139.2 ± 72.9 47.5 ± 27.4 IH-903 162.0 ± 63.5 39.6 ± 27.9 IH-904 139.8 ± 6.4 24.0 ± 38.2

IH-901, IH-902, IH-903 and IH-904 are the final metabolites by microorganisms such as gisenoside-Rb1, Rb2, Rc, and Rd of protopanaxadiol type in Ginsenosides of ginseng, blocking type IV collagenase secretion, The anti-angiogenic activity and inhibition of platelet aggregation result in potent anti-metastatic activites.

Among them, IH-901 inhibits cell proliferation very strongly by inhibiting normal differentiation of HL-60 cells, which are cancer cells, without toxicity and side effects, as revealed through pharmacological efficacy experiments, general pharmacological experiments, and stability experiments. The apoptosis-inducing effect of IH-901 is comparable to that of cisplatin, currently widely used as an anticancer drug.

Meanwhile, Korean Patent Application No. 1980-4291 "Method of manufacturing lactic acid bacteria ginseng drink" has the organic nitrogen concentration of 0.2-0.8% and the production content of glucose by enzymatically decomposing ginseng residues from the intrinsic fragrance of ginseng. It is disclosed that a method of adjusting the pH to 3.8 to 4.8 with an organic acid after removal of 3% suitable for fermentation, removing insoluble polymer protein and fiber, culturing the lactic acid bacteria in the eluate, and then adding ginseng's unique fragrance component is disclosed.

Republic of Korea Patent Application No. 1988-12502 "Method for producing active lactic acid bacteria beverages using ginseng" is based on the construction of enzymes in live juice or extract treated with ginseng, or by increasing the ginseng treatment or increase treatment of ginseng The present invention discloses a method of preparing carbonated aqueous beverages and ice creams of ginseng lactic acid bacteria having high nutritional value by adding and mixing skim milk, skim milk powder, carbonated water, and vitamins.

Republic of Korea Patent Application No. 1996-23750 "fermented milk composition containing ginseng or ginseng and a method for producing the same" is added to the process of adding 0.001 ~ 2.39% by weight of ginseng or ginseng, which is ground to form 0.1 ~ 0.6 cm fine A method for preparing a fermented milk composition containing ginseng or ginseng, comprising the step of adding one or two or more ingredients selected from the group consisting of water, vitamins, sugars, organic acids, fruits, grains and vegetables, are disclosed. .

As described above, the conventional ginseng-containing compositions were obtained by adding ginseng fragrance components or adding ginseng powder to conventional fermented milk or lactic acid bacteria beverages.

However, the ginseng-containing compositions are merely a beverage composition to which the ginseng component is added, which has a limitation in that anticancer ingredients such as IH-901, a metabolite of ginseng saponin, cannot be obtained.

In order to solve the above problems, an object of the present invention is to provide a bio-converted ginseng composition and anti-cancer component significantly enhanced anticancer components such as IH-901 and a method of manufacturing the same.

In addition, another object of the present invention to provide a bio-converted ginseng composition and a method for producing the same that can maximize the efficacy of the active ingredient contained in the ginseng raw materials.

In addition, another object of the present invention to provide a bioconversion ginseng composition having a beneficial effect on the human body, such as anti-allergy, anti-aging and colorectal cancer / liver damage prevention, and a method for producing the same.

In order to achieve the above object, in the ginseng composition, (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside Rb1 + Ginsenoside Rb2 Provided is a bioconversion ginseng composition characterized in that the ratio of) or more 0.1.

In addition, the present invention provides a method for producing a ginseng composition, the biological conversion process to obtain a bio-converted ginseng solution by suspending the ginseng raw material in water and incubated for 48 hours to 72 hours after lactic acid bacteria; It provides a method for producing a bio-converted ginseng composition comprising the step of centrifuging the bio-converted ginseng solution after the above process and filtering only the supernatant to obtain a bio-converted ginseng concentrate.

Hereinafter, exemplary embodiments of the present invention will be described in detail with reference to the accompanying drawings. In the following description of the present invention, if it is determined that the detailed description of the related known function or configuration may unnecessarily obscure the subject matter of the present invention, the detailed description thereof will be omitted.

The present invention provides a ginseng composition having a high content of IH-901 having excellent anticancer efficacy and stability in the final microbial metabolite of ginseng saponin and a method of preparing the same.

1 is a flow chart showing a method for producing a bioconversion ginseng composition according to a preferred embodiment of the present invention. As shown in FIG. 1, the method for preparing a bioconverted ginseng composition according to a preferred embodiment of the present invention includes a bioconversion process (S10) and a concentration process (S20), an extraction process (S30), and a drying process (S40). , A stirring process (S50) and a dilution process (S60) may be further performed.

1. Bioconversion process

The bioconversion process (S10) is a process of obtaining a bioconversion ginseng by suspending the ginseng raw material in water and then adding lactic acid bacteria or enterobacteriaceae and incubating for more than a predetermined time, preferably 24 to 72 hours.

 (1) ginseng raw materials

As the ginseng raw material of the present invention, any of ginseng and ginseng processed materials may be used. Preferably, any one or more of ginseng, red ginseng, white ginseng, rice ginseng, ginseng leaf, ginseng extract and ginseng powder may be used.

 (2) Lactobacillus and Enterobacteriaceae

Some of the lactic acid bacteria and enterobacteriaceae bioconvert the compounds contained in food or drugs, the biotransformers produced are often higher than the original compound. As shown in FIG. 2, compounds such as Ginsenoside-Rb1, Ginsenoside-Rb2, and Ginsenoside-Rc, which are contained in ginseng, the raw material of the present invention, are applicable to these cases, and they are lactic acid bacteria or enteric bacteria. Metabolized by) to the primary intermediate metabolites, Ginsenoside-Rd, Compound-O, Ginsenoside-Mc1 and secondary intermediate metabolites, Ginsenoside-F2, IH-902 (Compound-Y), and IH-903 (Compound-Mc). The final metabolite, IH-901 (Compound-K).

The lactic acid bacteria can be any one that can metabolize the ginseng saponin component to produce the bioconverter IH-901, preferably Biofidobacterium K-103, Biofidobacterium K-506, Bifobacterium KK-1, Bifidobacterium KK-2. Any one or more can be used. In particular, the Bifobacterium KK-1 was deposited as KCCM-10364 (2002.03.22) and the Bifidobacterium KK-2 was deposited as KCCM-10365 (2002.03.22) to the Korean Culture Center of Microorganisms, respectively. It has been deposited.

The enterobacteria may also be any one that can metabolize ginseng saponin components to produce the bioconverter IH-901, and preferably any one or more of Prevotella oris and Fusobacterium K-60.

2. Thickening process

The concentration process (S20) is a process of concentrating or freezing / drying the bioconversion ginseng as it is, or centrifuging the bioconversion ginseng solution and filtering only the supernatant to obtain a bioconversion ginseng concentrate. Through the concentration process (S20) it is possible to remove impurities and precipitates contained in the bioconversion ginseng solution.

3. Extraction process

The extraction process (S30) is a process of obtaining a bio-converted ginseng extract by administering a predetermined solvent to the bio-converted ginseng concentrate.

The solvent dissolves and extracts only the active ingredient contained in the bioconversion ginseng concentrate, and the solvent may be water, a lower alcohol such as methanol or ethanol, a supercritical fluid, or a mixture thereof.

4. Drying process

The drying process (S40) is a process of obtaining a bioconversion ginseng powder by freeze-drying the bioconversion ginseng extract.

5. Agitation process and dilution process

The stirring process and dilution process is a process performed to prepare a processed beverage using a bioconversion ginseng extract or bioconversion ginseng powder prepared according to the characteristics of the present invention.

The agitation process (S50) is a process of obtaining a bioconversion ginseng mixed solution by adding a bioconversion ginseng extract or a bioconversion ginseng powder into the mixed beverage stock solution and adding purified water to the sweetener. The beverage stock solution may be added any one or more of citric acid, sodium citrate, herbal extracts, taurine, depending on the application may be added herbal extracts, such as Schizandra chinensis, jujube, cinnamon, wolfberry, yellow, astragalus.

The dilution process (S60) is a process of obtaining a bioconversion ginseng beverage by adding a predetermined amount of purified water to the bioconversion ginseng mixture.

The bioconverted ginseng composition of the present invention prepared by the above process is (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside Rb1 + Ginsenoside Rb2 ) Ratio is maintained in the range of 0.1 or more. In this case, the 20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol) refers to IH-901.

<Example 1>

Extracted ginseng with water, dried and suspended 100 mg of ginseng powder obtained with water, and then strained with lactic acid bacteria Bifidobacterium K-103 and Bifidobacterium K-506, incubated for 72 hours, centrifuged, filtered only supernatant, concentrated and converted Ginseng concentrate was obtained.

<Example 2>

The extract obtained by cooling 1 kg of white ginseng with MeOH was again extracted with BuOH, and the suspension of saponin was suspended with water, and then strained with lactic acid bacteria Bifidobacterium K-103 and Bifidobacterium K-506, followed by incubation for 72 hours. After concentration, a bioconverted ginseng concentrate was obtained.

<Example 3>

Freshly chopped ginseng was suspended and sterilized with water, and then cultured for 48 hours after adding Lactobacillus Bifidobacterium K-103 and Bifidobacterium K-506 strain. Centrifugation was performed to filter only the supernatant and concentrated. Got.

<Example 4>

After extracting the dried ginseng with water and drying, 100 mg of ginseng powder obtained was suspended with water, and then strained with lactic acid bacteria Bifidobacterium KK-1 and Bifidobacterium KK-2, and incubated for 72 hours. Ginseng concentrate was obtained.

Example 5

The extract obtained by cooling 1 kg of white ginseng with MeOH was again extracted with BuOH, and the suspension of saponin was suspended with water, and then strained with lactic acid bacteria Bifidobacterium KK-1 and Bifidobacterium KK-2, and cultured for 72 hours. After concentration, a bioconverted ginseng concentrate was obtained.

<Example 6>

Freshly chopped ginseng was suspended and sterilized with water, and then incubated for 48 hours after adding Lactobacillus Bifidobacterium KK-1 and Bifidobacterium KK-2 strains, and centrifugation to filter only the supernatant, and concentrated by lyophilization. Got.

<Example 7>

Purified water is added to fructose, glucose and white sugar to dissolve it by heating to 95 DEG C, then slowly cooling to cool to 70 DEG C, stirring and dissolving with addition of citric acid, sodium citrate and sodium benzoate. Then, the Ogapi extract and taurine were dissolved while stirring. The bioconverted ginseng powder was added to the solution thus prepared, stirred well, and then purified water was added to a total volume of 100 ml, thereby preparing a beverage composition containing 250 mg of the bioconverted ginseng extract.

Experimental Example 1 Content Analysis 1

500 g of water was added to 2 g of white ginseng powder, 1 g of lactic acid bacteria Bifidobacterium KK-1 and Bifidobacterium KK-2 strains were added thereto, followed by incubation at 37 ° C. for 72 hours, and concentrated under reduced pressure to obtain a bioconverted ginseng concentrate. Then, the bioconverted ginseng concentrate and 2 g each of commercially available white ginseng were taken, extracted three times with 100 ml of methanol, concentrated, suspended in water, and extracted three times with 100 ml of ether. Then, after extracting three times with 100 mL of butanol, the butanol fraction was concentrated, and the obtained concentrate was dissolved in methanol and analyzed by TLC to obtain a result as shown in <Table 2>.

ingredient Content by Ingredient White ginseng Biotransformation Ginseng Ginsenoside Rb1 15.1 4.3 Ginsenoside Rb2 8.2 2.2 Ginsenoside Rc 9.5 1.1 Ginsenoside Rd 3.5 4.5 IH-901 0 16.1 Ginsenoside F2 <1 5.5 Protopanaxadiol <1 <1

(1) Lower layer of solvent CHCl ₃ : MeOH: H ₂ O = 65: 35: 10

                 (2) 5% MeOH Sulfate Solution

                 (3) Detector Shimadzu TLC scanner CS-9301PC

Experimental Example 2 Content Analysis 2

100 g of water was added to 1 g of white ginseng saponin fraction, 1 g of lactic acid bacteria Bifidobacterium KK-1 and Bifidobacterium KK-2 strains were added thereto, and cultured at 37 ° C. for 48 hours, and concentrated under reduced pressure to obtain a bioconversion ginseng concentrate. Subsequently, 1 g of each of the bioconversion ginseng concentrate and white ginseng saponin were dissolved in methanol, and analyzed by TLC to obtain a result as shown in Table 3 below.

ingredient Content by Ingredient White ginseng Biotransformation Ginseng Ginsenoside Rb1 15.1 1.6 Ginsenoside Rb2 8.2 1.1 Ginsenoside Rc 9.5 0.5 Ginsenoside Rd 3.5 0.5 IH-901 0 28.6 Ginsenoside F2 <1 2.2 Protopanaxadiol <1 2.1

(1) Lower layer of solvent CHCl ₃ : MeOH: H ₂ O = 65: 35: 10

                 (2) 5% MeOH Sulfate Solution

                 (3) Detector Shimadzu TLC scanner CS-9301PC

Experimental Example 3 Analysis of Anticancer Effect

HepG2 (Human liver cancer cell line), A-549 (Human lung cancer cell line), P-388 (Mouse lymphoid neoplasma cell line), L-1210 (Mouse lymphocytic leukemia cell line) 10% FBS, 1% antibiotics- Incubated with RPMI 1640 medium supplemented with antimycotics and 2.2 g / L sodium bicarbonate.

The HepG2, A-549 is by treatment with 0.25% trypsin Remove the cell from the cell number of the flask 3 x 10 ⁴ cell / well in accordance with the crushing 180㎕ in 96well with a 5% CO ₂ at 37 ℃ for 24 hours, saturated sikyeotgo attached in CO ₂ incubator, P-388 and L-1210 is a ⁴ x 10 4 / well is to be stabilized in accordance with the number of cell with a 5% CO ₂ for crushing a 180㎕ 2 sigan saturated CO ₂ incubator. After autoclaving to adjust the concentration of ginseng extract and bioconverted ginseng extract to 10 mg / ml, respectively, 20 μl per well was added so that the final concentration of the sample was 1 mg / ml. Incubated in a CO ₂ incubator saturated with% CO ₂ . After 48 hours, 50 μl of 20 mg / ml MTT reagent was added per well and reacted in a CO ₂ incubator for 4 hours. After removing the medium and adding 100 μl of DMSO to the precipitate, the absorbance was measured at 580 nm using an ELISA reader. Measured. The measurement results are as shown in Table 4 below.

division ED ₅₀ (Μg / ml) P388 L1210 A549 HepG2 Common Ginseng Extract > 100 > 100 > 100 > 100 Bioconversion Ginseng 98 50 160 96

Experimental Example 4: Analysis of Antiallergic Effect 1

RBL-2H3 cells (rat mast cell line) were cultured in a humidified 5% CO ₂ incubator at 37 ° C using Dulbeccos' Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum and L-glutamine. Was suspended using trypsin-EDTA solution to isolate and recover it, which was used in the experiment.

RBL-2H3 cells were dispensed into ⁵ wells at 5 x 10 ⁵ cell / well in 24 wells, and then incubated with mouse monoclonal IgE 0.5㎍ / ml for 12 hours and sensitized. The cells were washed with 0.5 ml of siraganian buffer (119 mM NaCl, 5 mM KCl, 0.4 mM MgCl ₂ , 25 mM PIPES, 40 mM NaOH, pH 7.2) and 0.16 ml of siraganian buffer (5.6 mM glucose, 1 mM CaCl ₂ , 0.1%). BSA was added) and then incubated at 37 ° C. for 10 minutes.

Next, after adding 0.04 ml of ginseng extract and 0.04 ml of bioconverted ginseng extract sample, 20 minutes passed, the cells were activated with 0.02 ml of antigen (DNP-BSA 1 µg / ml) at 37 ° C for 10 minutes, and then centrifuged at 2000 rpm for 10 minutes. Separately, 0.025 mL of supernatant was transferred to 96well. To this was added 0.025 ml of substrate solution 1 mM p-NAG (p-nitrophenyl-N-acetyl-β-D-glucosaminide in 0.1M citrate buffer pH 4.5) and incubated at 37 ° C. for 60 minutes, followed by 0.1M Na ₂ CO 0.2 ml of ₃ / NaHCO ₃ was added to stop the reaction, and the absorbance was measured by an ELISA reader at 405 nm. The measurement results are as shown in Table 5 below.

division IC ₅₀ (Mg / ml) Common Ginseng Extract > 0.25 Bioconversion Ginseng 0.103 Disodium cromoglycate 0.22

Experimental Example 5 Anti-allergic Effect Analysis 2-Histamine Free Inhibition

Male Wistar rats (200 ± 20g) were killed to measure anti-allergic effect using compound K 48/80 from intraperitoneal mice after physiological solution (137mM NaCl, 2.7mM CaCl ₂ , 1mM MgCl ₂ ㆍ 6H ₂ O, 20 ml of 5.6 mM glucose, 1 unit / ml of heparin, and 5 mM phosphate buffer pH7.2) were administered intraperitoneally. Then, the abdomen was lightly massaged for 2 minutes, and the peritoneal drainage liquid was again taken out by a syringe. Extracted ascites was centrifuged for 5 minutes at 300 × g, 4 ℃ and washed several times with physiological solution.

Subsequently, 0.5 ml of the physiological solution in which each sample was suspended at various concentrations was mixed in a peritoneal discharge cell suspension (2.5 ml) and preincubated at 37 ° C. for 5 minutes. Control and blank are handled in the same way. Then 0.5 ml of compound 48/80 was mixed into the reaction solution (3.0 ml) and incubated at 37 ° C. for 10 minutes. The reaction solution (3.5 mL) was centrifuged at 2500 × g, 4 ° C. for 10 minutes and the amount of histamine secreted from the supernatant and precipitate was measured. Histamine was quantified by the reaction of 0.6 ml of the supernatant, 1.4 ml of distilled water, 0.4 ml of 1N NaOH, and 0.1 ml of 1% o-phthaldialdehyde (in MeOH) at room temperature for 4 minutes. Jasco FP-750, excitation 353 nm, emmision 438 nm). The measurement results are as shown in Table 6 below.

Both ginseng and bioconverted ginseng showed histamine free inhibitory effects in rat mast cells induced with compound 48/80, especially bioconverted ginseng showed lower effect than ginseng extract. Could see. Therefore, it can be seen that the bioconversion ginseng composition of the present invention can be used as an anti-allergic substance by inhibiting the release of histamine when absorbed into the human body.

division IC ₅₀ (Mg / ml) Common Ginseng Extract 0.5 Bioconversion Ginseng 0.3 Disodium cromoglycate 0.22

Experimental Example 6 Analysis of Anti-Allergic Effect 3

This anti-allergic effect analysis 3 was performed according to the method of Inagaki et al. (Int. Arch. Allergy Appl. Immunol., 87, 254-259, 1988).

IgE serum for Dinitrophenol-bovine serum albumin (DNP-BSA) was injected into the back of anesthetized mice with 10 μl diluted with physiological saline and passively sensitized. 0.2ml of saline solution is injected into the tail vein and killed by cervical dislocation 30 minutes later to measure the amount of evans blue pigment leaked on the back. Cut a portion of the back of the mouse, put it in a test tube, add 0.7 ml of 1N-KOH and incubate overnight at 37 ℃. To the test tube, 4 ml of 0.6N phosphoric acid: acetone mixture (5:13) was added, followed by shaking and filtration to colorimetrically extract the extracted pigment at 620 nm. Next, the ginseng extract and the bioconverted ginseng extract are dissolved or suspended in physiological saline, respectively, and administered orally or intraperitoneally 1 hour before administration. The measurement results are as shown in Table 7 below.

division Volume (Mg / kg) Inhibition (%) Oral administration Intraperitoneal administration Common Ginseng Extract 50 0 5 Bioconversion Ginseng 50 48 52 Disodium cromoglycate 100 37 Unmeasured

Experimental Example 7: Antioxidant Effect-Anti-aging by Radical Scavenging

In order to measure the DPPH (1,1-diphenyl-2-picrylhydrazyl) radical scavenging effect, 500 μl of 60 μM DPPH (in EtOH) was added to the reaction solution in 500 μl of the sample and reacted at room temperature for 30 minutes, and then absorbance was measured at 520 nm. EtOH was used instead of DPPH as a blank, and 100% of water was used instead of the sample as a control, and the degree of DPPH radical removal was calculated as%. Caffeic acid was used as a control drug.

In addition, in order to measure the superoxide anion radical scavenging effect, 900 mM of 0.05 mM Na ₂ CO ₃ (pH 10.2) was added to 3 mM xanthine (Sigma), 3 mM EDTA (Sigma), and 1.5 µg / ml BSA (Sigma). 50 μl of 0.75 mM NBT (Sigma) was added, respectively. 50 μl of the sample and 50 μl of 0.1 μg / ml xanthine oxidase were added thereto, followed by reaction for 30 minutes. 6 mM CuCl ₂ was added to stop the reaction, and the absorbance was measured at 560 nm. Caffeic acid was used as a control drug.

Ginseng saponin fraction was not strong in antioxidative effect. However, bioconversion ginseng was superior to general ginseng, and this antioxidant effect can be expected to prevent aging. The measurement results are as shown in Table 8 below. Therefore, it can be seen that the bioconversion ginseng composition of the present invention can be used as an anti-aging material because it causes an antioxidant action due to radical scavenging when absorbed into the human body.

division 50% Inhibitory Concentration (mM) DPPH radical Super oxide radical Common Ginseng Extract 0.8 0.14 Bioconversion Ginseng 0.7 0.11 Caffeic acid 0.004 0.004

Experimental Example 8 Inhibition Effect of Colorectal Cancer / Liver Damage Inducing β-glucuronidase

Β-glucurondase produced by human intestinal bacteria causes colorectal cancer and liver damage, and it is known that inhibitors of this enzyme have the effect of preventing colorectal cancer and liver damage (DH Kim, IS Jang, JB Park, SW Lee). , Protective roles of mushrooms in experimental colon carcinogenesis.Arch.Parm.Res. 18, 79-83, 1995; DH Kim, SB Shim, NJ Kim, IS Jang, β-glucuronidase-inhibitory activity and hepatoprotective effects of Ganoderma lucidum. Pharm.Bull. 22, 162-164, 1999).

Accordingly, the method of Kim et al. (DH Kim, SB Shim, NJ Kim, IS Jang, -Glucuronidase-inhibitory activity and hepatoprotective effects of Ganoderma lucidum. Biol. Pharm. Bull. 22, 162-164, 1999).

First, Escherichia coli HGU-3 strains isolated from human intestines were cultured to purify β-glucuronidase according to Kim et al. 50mM phosphate buffer 0.38ml, 20mM p-nitrophenyl-β-D-glucuronide (Sigma, USA) 0.02ml, water or ginseng extract 0.05ml and enzyme solution 0.05ml and reacted for 30 minutes, 0.2N NaOH 0.5ml The inhibitory activity was calculated by stopping and measuring the absorbance at 405 nm.

The measurement results are shown in Table 9 below. As a result of the measurement, it can be seen that the bioconverted ginseng of the present invention can be used as a material for preventing colon cancer and liver damage by inhibiting β-glucuronidase causing colon cancer and liver damage.

division IC ₅₀ (Mg / ml) Common Ginseng Extract 0.2 Bioconversion Ginseng 0.1 Saccharic acid 1,4-lactone 0.004

As described above, the bioconversion ginseng composition and the preparation method according to the embodiment of the present invention are (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside By maintaining the ratio of Rb1 + Ginsenoside Rb2) to 0.1 or more, there is an effect of providing a bioconverted ginseng composition having significantly enhanced anticancer components.

In addition, the bioconversion ginseng composition according to an embodiment of the present invention and a method for producing the same by bioconversion of the saponin component contained in the ginseng raw material to produce a metabolite with high physiological activity, low content of active ingredients such as saponin, ginseng processed product Ginseng leaves, which were not suitable for use as raw materials, can also be used as raw materials.

In addition, the bio-converted ginseng composition according to an embodiment of the present invention and a method for producing the same have an antiallergic effect by inhibiting the release of histamine when absorbed into the human body, causing antioxidant activity due to radical scavenging, and inhibiting aging. It inhibits the production of β-glucurondase, which is effective in preventing colon cancer and liver damage.

1 is a flow chart showing a method for producing a bio-converted ginseng composition according to a preferred embodiment of the present invention,

Figure 2 is a schematic diagram showing the metabolic process of ginseng saponin.

<Explanation of symbols for the main parts of the drawings>

S10: Bioconversion Process S20: Concentration Process

S30: Extraction Process S40: Drying Process

S50: stirring process S60: dilution process

Claims (16)

delete In the ginseng composition, The ratio of (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside Rb1 + Ginsenoside Rb2) is 0.1 or higher, and the absorption of histamine upon absorption by the human body Bioconversion ginseng composition, characterized in that used as an anti-allergic substance. In the ginseng composition, The ratio of (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside Rb1 + Ginsenoside Rb2) is at least 0.1, and due to radical scavenging upon absorption by the human body Bioconversion ginseng composition, characterized in that it is used as an anti-aging substance by causing antioxidant activity. In the ginseng composition, The ratio of (20-0-β-D-glucopyranosyl-20 (S) -protopanaxadiol + Ginsenoside F) / (Ginsenoside Rc + Ginsenoside Rd + Ginsenoside Rb1 + Ginsenoside Rb2) is 0.1 or more and enterobacteria are produced when absorbed by the human body. Bio-converted ginseng composition characterized by inhibiting the production of β-glucurondase to be used as a substance for preventing colon cancer and liver damage. In the manufacturing method of the ginseng composition, After suspending ginseng raw materials using any one or more of ginseng, red ginseng, white ginseng, rice ginseng, ginseng leaf, ginseng extract and ginseng powder in water, Bifobacterium KK-1, Bifidobacterium KK-2, Biofidobacterium K-103, Biofidobacterium K- A bioconversion process of obtaining one or more lactic acid bacteria of 506 and incubating for about 24 hours to 72 hours to obtain a bioconversion ginseng solution; Concentrating or freezing / drying the bio-converted ginseng solution through the process as it is, or centrifugation of the bio-converted ginseng solution and filtering only the supernatant of the bio-converted ginseng composition comprising the step of obtaining Manufacturing method. delete delete delete delete delete delete delete delete delete delete delete